ClinVar Miner

Submissions for variant NM_000051.3(ATM):c.4362A>C (p.Lys1454Asn) (rs148993589)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000212012 SCV000883421 uncertain significance not provided 2017-07-03 criteria provided, single submitter clinical testing The p.Lys1454Asn variant has been reported in individuals with breast cancer (Broeks 2008 Teraoka 2001, Tavtigian 2009), endometrial cancer (Ring 2016), and idiopathic perifoveal telangiectasia (Barbazetto 2008) but has not been reported in association with ataxia telangiectasia. This variant is listed in the genome Aggregation Database (gnomAD) with an overall population frequency of 0.03 percent (identified on 84 out of 276,958 chromosomes) and has been reported to ClinVar (Variation ID: 127386). The lysine at position 1454 is moderately conserved (Alamut v.2.9.0) and computational analyses of the effects of the p.Lys1454Asn variant on protein structure and function predict a neutral effect (SIFT: tolerated, Align GVGC: C0 (benign), PolyPhen-2: benign). Altogether, there is not enough evidence to classify the p.Lys1454Asn variant with certainty.
Ambry Genetics RCV000115191 SCV000186552 benign Hereditary cancer-predisposing syndrome 2015-06-28 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: In silico models in agreement (benign),Internal frequency is too high to be a pathogenic mutation based on disease/syndrome prevalence and penetrance,Other strong data supporting benign classification
Color RCV000115191 SCV000682199 uncertain significance Hereditary cancer-predisposing syndrome 2018-06-04 criteria provided, single submitter clinical testing
GeneDx RCV000212012 SCV000149100 uncertain significance not provided 2018-10-16 criteria provided, single submitter clinical testing This variant is denoted ATM c.4362A>C at the cDNA level, p.Lys1454Asn (K1454N) at the protein level, and results in the change of a Lysine to an Asparagine (AAA>AAC). This variant has been observed in individuals with breast, endometrial, or colon cancer (Maillet 2002, Broeks 2008, Lu 2015, Tung 2015, Ring 2016, Decker 2017, Pearlman 2017, Hampel 2018, Hauke 2018), and was reported in 3/987 breast cancer cases but absent among 1021 controls in a breast cancer case-control meta-analysis (Tavtigian 2009). Additionally, ATM Lys1454Asn has been identified in an individual with idiopathic perifoveal telangiectasia (Barbazetto 2008). ATM Lys1454Asn was observed at an allele frequency of 0.06% (76/126,554) in individuals of European ancestry in large population cohorts (Lek 2016). This variant is not located in a known functional domain. In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function. Based on currently available evidence, it is unclear whether ATM Lys1454Asn is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Invitae RCV000198920 SCV000254104 uncertain significance Ataxia-telangiectasia syndrome 2018-04-23 criteria provided, single submitter clinical testing This sequence change replaces lysine with asparagine at codon 1454 of the ATM protein (p.Lys1454Asn). The lysine residue is moderately conserved and there is a moderate physicochemical difference between lysine and asparagine. This variant is present in population databases (rs148993589, ExAC 0.07%). This variant has been reported in individuals with breast cancer (PMID: 11505391, 17393301, 19781682, 26689913), and an individual with endometrial carcinoma (PMID: 27443514). ClinVar contains an entry for this variant (Variation ID: 127386). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
PreventionGenetics RCV000212012 SCV000805560 uncertain significance not provided 2017-07-06 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.